HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Bendamustine Hydrochloride

HCID 77082
New reaction
Print
Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
3543-75-7
Standard SMILES
Cl.Cn1c(CCCC(=O)O)nc2cc(N(CCCl)CCCl)ccc21
InChIKey
ZHSKUOZOLHMKEA-UHFFFAOYSA-N
Molecular formula
C16H22Cl3N3O2
Average molar mass
394.7 g/mol
Monoisotopic mass
393.07776

Overview

Bendamustine Hydrochloride is the hydrochloride salt of bendamustine, a bifunctional mechlorethamine derivative with alkylator and antimetabolite activities. Bendamustine possesses three active moieties: an alkylating group; a benzimidazole ring, which may act as a purine analogue; and a butyric acid side chain. Although its exact mechanism of action is unknown this agent appears to act primarily as an alkylator. Bendamustine metabolites alkylate and crosslink macromolecules, resulting in DNA, RNA and protein synthesis inhibition, and, subsequently, apoptosis. Bendamustine may differ from other alkylators in that it may be more potent in activating p53-dependent stress pathways and inducing apoptosis; it may induce mitotic catastrophe; and it may activate a base excision DNA repair pathway rather than an alkyltransferase DNA repair mechanism. Accordingly, this agent may be more efficacious and less susceptible to drug resistance than other alkylators.

Names & identifiers

Preferred name
Bendamustine Hydrochloride
IUPAC
4-[5-[bis(2-chloroethyl)amino]-1-methylbenzimidazol-2-yl]butanoic acid;hydrochloride
English name
Bendamustine hydrochloride
Molecular formula
C16H22Cl3N3O2
Molecular weight
394.72

Names & synonyms

Bendamustine hydrochloride3543-75-7Bendamustine HClTreandaRibomustinBendekaBendamustin hydrochlorideRibomustineSyB L-0501VIVIMUSTALevactbendamustin
Show more names
BendaMustine hydrochloride hydrateEP3101SDX 105DD6304600CYTOSTASANZIMET-33/93Cytostasane
NSC-138783SYBL-0501981Y8SX18MDTXSID40188912NSC1387831H-Benzimidazole-2-butanoic acid, 5-(bis(2-chloroethyl)amino)-1-methyl-, monohydrochloride2-Benzimidazolinebutryric acid, 1-methyl-5-bis(2-chloroethyl)amino-, hydrochlorideBelrapzo

Database identifiers

CAS
3543-75-7
PubChem CID
77082
DTXSID
DTXSID40188912
ChEMBL
CHEMBL1201734
UNII
981Y8SX18M
EC Number
631-540-0

Properties

Computed structural properties

Topological polar surface area
58.4 Ų
Hydrogen bond donors
2
Hydrogen bond acceptors
4
Rotatable bonds
9
Heavy atoms
24
Formal charge
0
Complexity
380

Experimental & physicochemical properties

Human Drugs · 3 items

Breast Feeding; Lactation; Antineoplastic Agents, Alkylating; Nitrosourea Compounds

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Physicochemical properties

Melting point
149 · 149-151°C
storage temp.
room temp
solubility
2 O: · H2O: >30mg/mL
form
powder
color
off-white
Merck
14 · 14,1034
Major Application
(Pharmaceutical small molecule)
InChI
InChI=1S/C16H21Cl2N3O2.ClH/c1-20-14-6-5-12(21(9-7-17)10-8-18)11-13(14)19-15(20)3-2-4-16(22)23;/h5-6,11H,2-4,7-10H2,1H3,(H,22,23);1H
InChIKey
ZHSKUOZOLHMKEA-UHFFFAOYSA-N
SMILES
C12N=C(CCCC(=O)O)N(C)C=1C=CC(N(CCCl)CCCl)=C2.Cl
CAS DataBase Reference
3543 · 3543-75-7(CAS DataBase Reference)

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 4 items

Danger

H301 (95.9%): Toxic if swallowed [Danger Acute toxicity, oral]

P203, P264, P270, P280, P301+P316, P318, P321, P330, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 49 reports by companies from 12 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Hazard information

Hazard Classes and CategoriesAcute Tox. 3 (95.9%)

Toxicology

Drug Induced Liver Injury · 6 items

Drug Induced Liver Injury Rank (DILIrank 2.0)

Bendamustine hydrochloride

vNo-DILI-concern

0

No match

DOI:10.1016/j.drudis.2016.02.015

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

Safety data

wgk
3
rtecs
DE1590000
ridadr
UN 2811 6.1 / PGIII
hs_code
2933990099
Toxicity
LD50 (monohydrate) in mice, rats (mg/kg): 400-500, 200-300 orally; 80, 40 i.v. (Horn)
risk_code
60-61-22-40
Signal word
Danger

Chemistry & industry

Pharmacology

FDA Pharmacological Classification · 4 items

BENDAMUSTINE HCL

Alkylating Activity [MoA]; Alkylating Drug [EPC]

BENDAMUSTINE HYDROCHLORIDE

Alkylating Activity [MoA]; Alkylating Drug [EPC]

MeSH Pharmacological Classification · 1 item

A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026)

Applications · 6 items

DescriptionBendamustine is a purine analog and DNA alkylating agent. It inhibits growth of SKW-3, Reh, CML-T1, BV-173, and HL-60 leukemia cell lines (IC50s = 27.0, 28.6, 15.6, 20.8, and 57.7 μM, respectively) but not MCF-7 and MDA-MB-231 breast cancer cell lines (IC50s = >200 and >200 μM, respectively). It kills B cell-chronic lymphocytic leukemia (B-CLL) cells derived from naïve and bendamustine-pretreated patients (LD50s = 6.8-8.3 and 3.8-4.9 mg/ml, respectively). Bendamustine (50 mg/kg) inhibits tumor growth by 9% and 96% alone and in combination with ofatumumab, respectively, in a JVM-3 CLL mouse xenograft model. It activates the DNA-damage stress response, the base excision DNA repair pathway, and apoptosis, as well as inhibits mitotic checkpoints and induces mitotic catastrophe. Formulations containing bendamustine have been used to treat CLL and non-Hodgkin lymphoma.

UsesUsed as an anticancer drug

UsesBendamustine HCL is a DNA-damaging agent with IC50 of 50 μM.

Usesalkylating agent recently approved by the FDA for treatment of Chronic Lymphocytic Leukemia

UsesBendamustine hydrochloride hydrate has been used as: a chemotherapy agent for chronic lymphocytic leukemia (CLL) samples to monitor spliced and unspliced gene expression an inhibitor to E3 ubiquitin-protein ligase RNF3 (HOIP) inmatrix-assisted laser desorption ionization time-of-flight mass spectrometry(MALDI-TOF) assaya cytotoxic chemotherapeutic drug in high-throughput screening to test interaction with BAY87-2243

Related reactions

23 records
New reaction record
HRID 628812 reaction equation
HRID 628812As reactant
HRID 631038 reaction equation
HRID 631038As reactant
HRID 1746113 reaction equation
HRID 1746113As reactant
HRID 1746114 reaction equation
HRID 1746114As reactant
HRID 1746115 reaction equation
HRID 1746115As reactant
HRID 1746116 reaction equation
HRID 1746116As reactant
HRID 1746117 reaction equation
HRID 1746117As reactant
HRID 1746118 reaction equation
HRID 1746118As reactant
PreviousPage 1 of 3

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
NCI Dictionary of Cancer Terms
bendamustine hydrochloride; Treanda
FDA UNII
981 Y8SX18M · 981Y8SX18M
NCI Drug Dictionary
bendamustine hydrochloride
Comptox DTXSID
40188912 · DTXSID40188912
NACRES
24 · NA.24
Protein binding
95 % · >95%
Excreted unchanged in urine
3 · 3 (20% as unchanged drug and metabolites)
Volume of distribution
15.8 · 15.8-20.5 Litres
Biological half-life
28.2 minutes · 28.2 minutes / -
Symbol(GHS)
6 · GHS06,GHS08
Signal word
Danger
Hazard statements
301 · H301-H341-H351-H361fd
Precautionary statements
201 · P201-P202-P264-P270-P280-P301+P310
Hazard Codes
T,Xn
Risk Statements
60 · 60-61-22-40
Safety Statements
36 · 36-37
RIDADR
2811 · UN 2811 6.1 / PGIII
WGK Germany
3 · 3
RTECS
1590000 · DE1590000
HazardClass
6.1 · 6.1
PackingGroup
III
HS Code
2933990099 · 2933990099
Storage Class
6.1 C · 6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects
Hazard Classifications
3 OralCarc · Acute Tox. 3 OralCarc. 2Muta. 2Repr. 2
Toxicity
50 · LD50 (monohydrate) in mice, rats (mg/kg): 400-500, 200-300 orally; 80, 40 i.v. (Horn)
Symbol(GHS)
GHS06,GHS08
hazard_code
T,Xn
safety_code
36-37
hazard_class
6.1
Storage Class
6.1C - Combustible acute toxic Cat.3toxic compounds or compounds which causing chronic effects
packing_group
III
Hazard statements
H301-H341-H351-H361fd
Hazard Classifications
Acute Tox. 3 OralCarc. 2Muta. 2Repr. 2
Precautionary statements
P201-P202-P264-P270-P280-P301+P310

General DescriptionBendamustine comprises 2-chloroethylamine alkylating group, a butyric acid side chain and a benzimidazole ring in its structure and is a nitrogen mustard. It is catabolized in the liver by the enzyme cytochrome P450 1A2 into γ hydroxyl-bendamustine and N-desmethyl-bendamustine.

Upstream & downstream products

Upstream raw materials

Pentanoic acid, 5-[(2,4-dinitrophenyl)methylamino]-5-oxo-, methyl esterPentanoic acid, 5-[(2,4-dinitrophenyl)amino]-5-oxo-, methyl esterisopropyl 4-(1-methyl-5-nitro-1H-benzo[d]imidazol-2-yl)butanoate5-[Bis(2-chloroethyl)aMino]-1-Methyl-1H-benziMidazole-2-butanoic Acid Methyl Ester1H-Benzimidazole-2-butanoic acid, 5-[bis(2-hydroxyethyl)amino]-1-methyl-, 1-methylethyl ester2,4-Dinitrochlorobenzene5-[Bis(2-hydroxyethyl)amino]-1-methyl-1H-benzimidazole-2-butanoic acid ethyl esterMethyl 4-(chloroformyl)butyrateBendaMustine IMpurity C2,4-Dinitroaniline5-[Bis(2-hydroxyethyl)amino]-1-methyl-1H-benzimidazole-2-butanoic acid methyl esterN-methyl-2,4-dinitroanilineN1-Methyl-4-nitro-o-phenyldiamin